Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Prothelia Inc
Profile last edited on: 5/27/14      CAGE: 4ZDG6      UEI:

Business Identifier: Therapeutics for muscular dystrophy
Year Founded
2007
First Award
2009
Latest Award
2010
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

30 Haven Street
Milford, MA 01757
   (508) 561-9298
   brad.hodges@prothelia.com
   www.prothelia.com
Location: Single
Congr. District: 04
County: Worcester

Public Profile

Prothelia is developing pharmaceuticals for Duchenne muscular dystrophy (DMD), Congenital muscular dystrophy type 1A (MDC1A) and Dystrophin-deficient and X-linked dilated cardiomyopathy (XLDCM)

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$967,793
Phase II Dollars
$25,195
Total Awarded
$992,988

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2010 1 NIH $503,756
Project Title: Hit To Lead Optimization Of Small Molecule Therapeutics For Muscular Dystrophy
2010 1 NIH $237,296
Project Title: Intravenous Protein Therapy For Treatment Of Congenital Muscular Dystrophy
2009 1 NIH $251,936
Project Title: Intravenous Protein Therapy for the Treatment of Duchenne Muscular Dystrophy

Key People / Management

  Rich Cloud -- President and CEO

  Bradley L Hodges -- Founder and CSO

Company News

Feb 03 2011
University of Nevada, Reno muscular dystrophy work featured in "Better World Report": Tech Transfer Office inks licensing deal with Prothelia for development of new therapy